Immutep Limited logo
Immutep Limited IMMP
$ 2.65 -0.94%

Annual report 2025
added 02-21-2026

report update icon

Immutep Limited Net Debt 2011-2026 | IMMP

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Immutep Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- -17.4 M -8.93 M -16.8 M -6.46 M -15.9 M -5.25 M -14.2 M -22 M -17 M -45.9 M

All numbers in AUD currency

Indicator range from annual reports

Maximum Minimum Average
-5.25 M -45.9 M -17 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
12.5 M $ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
-33.4 M - -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-311 M $ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
-27.6 M - 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-48 M - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
1.44 B $ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
533 K - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 8.52 -2.46 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
-206 M - - $ 3.45 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
17.5 M - - $ 789 M usaUSA
Certara Certara
CERT
105 M $ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-40.8 M - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-22.3 M - -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
293 M - -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-12.1 M - - $ 231 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
-12.5 M $ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
-706 M $ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
12.5 M $ 0.99 -3.28 % $ 72.7 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
-10.6 M $ 17.75 -0.79 % $ 852 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
18.3 M - - $ 1.2 B usaUSA
CohBar CohBar
CWBR
-2.2 M - -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-3.34 M - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-3.34 M - -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
-57.6 M - - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
-158 M $ 20.02 -4.67 % $ 3.29 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
-10.8 M $ 17.54 -3.36 % $ 450 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
-55.1 M - - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
-475 K - 7.55 % $ 38.1 M usaUSA